Modified mRNA 5'-Cap Analogs Enhancing Stability and Translation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mRNA therapeutic approaches face challenges in improving capping efficiency, enhancing resistance against decapping machinery, and optimizing binding to polymerases, particularly for in vitro transcription and translation, due to limitations in natural nucleoside modifications.
Innovation Solution
Development and synthesis of novel 5′-cap analogs with modified nucleobases and triphosphate linkers to enhance mRNA stability, translation efficiency, and durability, including compounds like those described in formulas (I) and (II), which can be incorporated into mRNA molecules for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural 7-methylguanosine cap structure is used, then mRNA can be recognized by protein synthesis machinery, but mRNA stability is limited and resistance against decapping machinery is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the 5' cap analogs through various substitutions including 2'-O-methyl, 2'-O-ethylene, phosphorothioate linkages, and locked nucleic acid modifications. These structural parameter changes enhance mRNA stability and resistance to decapping machinery while maintaining recognition by translation initiation factors, thereby extending mRNA half-life without sacrificing functionality.
Solution Approach 2:
The patent employs composite materials by combining multiple modified nucleoside components within the cap analog structure. The cap analogs incorporate hybrid modifications such as 7-methylguanosine coupled with 2'-O-methyl or 2'-O-ethylene modified nucleotides through phosphorothioate linkers, creating composite structures that simultaneously provide stability, resistance to degradation, and proper cellular recognition.
2Productivity
If conventional 5' cap analogs are used, then in vitro transcription can proceed, but capping efficiency and binding to polymerases are not optimized
Solution Approach 1:
The patent optimizes capping efficiency and polymerase binding through parameter changes in the cap analog structure, including modifications at the 2' position of ribose (2'-O-methyl, 2'-O-ethylene), phosphorothioate linkages, and locked nucleic acid configurations. These parameter adjustments enhance both the efficiency of in vitro transcription capping and the affinity binding to T7 polymerase, resolving the contradiction between productivity and reliability.
3Ease of manufacture
If simple 7-methylguanosine cap is used, then manufacturing is straightforward, but translation efficiency and durability are insufficient
Solution Approach 1:
The patent achieves enhanced translation efficiency while maintaining manufacturing feasibility through parameter changes in the cap analog structure. The modifications include 2'-O-methyl and 2'-O-ethylene groups on the first and second nucleotides, phosphorothioate linkages, and locked nucleic acid modifications. These changes improve translation efficiency and mRNA durability without significantly complicating the in vitro transcription capping process, as the modified nucleotides can be incorporated using standard enzymatic capping protocols.
Data Source
AI summary
The invention provides 5′-cap analogs, which can improve transcription, mRNA stability, and mRNA translation efficiency and durability. This invention also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.